How to buy Predictive Oncology stock | $1.18

Predictive Oncology Inc is a medical instruments & supplies business based in the US. Predictive Oncology shares (POAI) are listed on the NASDAQ and all prices are listed in US Dollars. Predictive Oncology employs 22 staff and has a trailing 12-month revenue of around 0.00.

Predictive Oncology stock price (NASDAQ: POAI)

Use our graph to track the performance of POAI stocks over time.

Predictive Oncology shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$1.18
52-week range	$0.63 - $2.30
50-day moving average	$1.14
200-day moving average	$1.26
Wall St. target price	$5.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.43

Buy Predictive Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Predictive Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Predictive Oncology Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Predictive Oncology price performance over time

Historical closes compared with the close of $1.18 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	-2.48%
3 months (2021-05-03)	9.26%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Predictive Oncology financials

Revenue TTM	$1.2 million
Gross profit TTM	$805,080
Return on assets TTM	-24.77%
Return on equity TTM	-109.99%
Profit margin	0%
Book value	$0.73
Market capitalisation	$73.8 million

TTM: trailing 12 months

Shorting Predictive Oncology shares

There are currently 1.5 million Predictive Oncology shares held short by investors – that's known as Predictive Oncology's "short interest". This figure is 2.1% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Predictive Oncology shares can be evaluated.

Predictive Oncology's "short interest ratio" (SIR)

Predictive Oncology's "short interest ratio" (SIR) is the quantity of Predictive Oncology shares currently shorted divided by the average quantity of Predictive Oncology shares traded daily (recently around 4.4 million). Predictive Oncology's SIR currently stands at 0.34. In other words for every 100,000 Predictive Oncology shares traded daily on the market, roughly 340 shares are currently held short.

However Predictive Oncology's short interest can also be evaluated against the total number of Predictive Oncology shares, or, against the total number of tradable Predictive Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Predictive Oncology's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Predictive Oncology shares in existence, roughly 20 shares are currently held short) or 0.0316% of the tradable shares (for every 100,000 tradable Predictive Oncology shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Predictive Oncology.

Find out more about how you can short Predictive Oncology stock.

Predictive Oncology share dividends

We're not expecting Predictive Oncology to pay a dividend over the next 12 months.

Have Predictive Oncology's shares ever split?

Predictive Oncology's shares were split on a 1:10 basis on 28 October 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Predictive Oncology shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Predictive Oncology shares which in turn could have impacted Predictive Oncology's share price.

Predictive Oncology share price volatility

Over the last 12 months, Predictive Oncology's shares have ranged in value from as little as $0.63 up to $2.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Predictive Oncology's is 1.9543. This would suggest that Predictive Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Predictive Oncology overview

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases.

Frequently asked questions

What percentage of Predictive Oncology is owned by insiders or institutions?
Currently 7.675% of Predictive Oncology shares are held by insiders and 7.456% by institutions. How many people work for Predictive Oncology?
Latest data suggests 22 work at Predictive Oncology. When does the fiscal year end for Predictive Oncology?
Predictive Oncology's fiscal year ends in December. Where is Predictive Oncology based?
Predictive Oncology's address is: 2915 Commers Drive, Eagan, MN, United States, 55121 What is Predictive Oncology's ISIN number?
Predictive Oncology's international securities identification number is: US74039M2008 What is Predictive Oncology's CUSIP number?
Predictive Oncology's Committee on Uniform Securities Identification Procedures number is: 09071P109